Weekly FDA Roundup: MAHA Takes Shape in Policy, 28 Recalls, and a Wound Care Alert — Week of Jan 17–24, 2026
FDA issued a MAHA-driven gluten labeling RFI, reported ImportShield efficiency gains, and posted five warning letters — alongside 28 recalls and a serious wound care device alert from Integra LifeSciences.
The week of January 17–24 was defined by two FDA actions framed explicitly around the MAHA strategy — a sweeping Request for Information on gluten labeling and a report touting the ImportShield program's efficiency gains — alongside 28 recalls, five warning letters, and a medical device safety alert with confirmed injuries. This was a lighter enforcement week by volume, but the policy signals were loud.
By the Numbers
| Metric | Count |
|---|---|
| Total items (Jan 17–24) | 40 |
| Recalls | 28 |
| Federal Register notices | 8 |
| Warning letters | 5 |
| Press releases | 2 |
| Safety alerts | 1 |
Class I recalls (the most severe) accounted for at least six of the enforcement actions, touching supplement companies, a bakery, a chocolate maker, and a grocery retailer's prepared foods.
Lead Story: FDA Moves on Gluten Labeling Under MAHA Mandate
On January 21, FDA issued a Request for Information on gluten labeling and cross-contact prevention in packaged foods — the most direct regulatory action yet tied to the Make America Healthy Again (MAHA) agenda. HHS Secretary Robert Kennedy Jr. called it a step toward "radical transparency in packaged food ingredients," and FDA Commissioner Marty Makary cited data gaps that prevent the agency from fully evaluating the risks of rye, barley, and oat cross-contact for people with celiac disease.
The RFI is open for 60 days (Docket No. FDA-2023-P-3942) and seeks information on:
- The prevalence of products where rye or barley are not currently disclosed on packaging
- Severity and potency of IgE-mediated food allergy to rye and barley
- Gluten content of oats due to cross-contact during production
This matters beyond the celiac community. The RFI is the opening move toward potential new labeling rules that could require disclosure of non-wheat gluten-containing grains — currently not mandated as major food allergens under FALCPA. For any food manufacturer using shared equipment or processing lines that touch barley, rye, or oats, this is the moment to track your labeling exposure. The agency says it intends to use responses to "support a determination on what type(s) of future regulatory actions we should take." That language means rulemaking is on the table.
The same day, FDA published a companion press release framing the gluten action alongside the MAHA strategy's broader push for ingredient transparency — a sign the new administration is using food labeling as a primary lever for its public health agenda.
Key Developments
FDA ImportShield Claims 66% Speed Gains at Ports of Entry
FDA released its first public scorecard on the ImportShield Program (FISP), which launched in August 2025 by consolidating five regional import review teams into a single centralized operation. In four months, FDA says FISP achieved:
- 66% increase in processing speed
- 33% increase in monthly volume capacity (admissibility decisions rose from 58 million to 75 million lines year-over-year)
- 20% reduction in staff hours — saving approximately 3,388 hours per month
The practical consequence: nationwide real-time alerts when high-risk products — such as tainted infant formula or counterfeit medications — are detected at any single port. Importers and customs brokers should note that this consolidated structure makes it harder to exploit gaps between regional teams. The agency is also building an advanced review platform that will integrate multiple databases, with connectivity to CBP systems.
Integra LifeSciences MediHoney Recall — 11 Confirmed Serious Injuries
On January 22, FDA issued an Early Alert for Integra LifeSciences' MediHoney Wound and Burn products — including multiple calcium alginate dressings, gel tubes, and certain CVS Wound Gel lots. The root cause: packaging failures that breach the sterile barrier, potentially causing patient infection.
As of December 19, 2025, Integra reported 11 serious injuries associated with MediHoney products and 3 additional serious injuries with CVS Wound Gel. No deaths were reported. All lots of MediHoney products are affected. Healthcare facilities using these products should identify and quarantine inventory immediately. The alert was subsequently classified as a Class II recall in March 2026.
For wound care procurement teams: check SKUs 31012, 31022, 31045, 31805, and 31815 against current inventory.
Three Medical Device Companies Hit for IDE/PMA Violations in a Single Day
On January 20, FDA published three warning letters to device companies for Investigational Device Exemption (IDE) / Premarket Approval (PMA) violations: Genovate (letter dated 01/08/2026), Genetrace (letter dated 01/08/2026), and Germaphobix (letter dated 01/09/2026). Three companies, one category of violation, two consecutive business days of issuance. The simultaneous posting suggests coordinated enforcement against companies conducting device investigations without adequate FDA authorization — a pattern that parallels the GLP-1 compounding crackdown in pharma.
Device companies conducting clinical studies should treat this as a signal that IDE compliance is under renewed scrutiny.
A fourth warning letter the same day targeted Integrity Partners Group for CGMP violations in finished pharmaceuticals, and a fifth went to Prodrome Sciences USA, LLC for marketing unapproved and misbranded drug products — five total letters posted on a single date.
Navitas Organics Chia Seeds Recalled for Salmonella
Navitas Organics voluntarily recalled select lots of its 8oz Organic Chia Seeds on January 23 due to potential Salmonella contamination, tracing back to the company's chia seed supplier. The recall affects eight lot codes (beginning with "W") with best-by dates through May 2027. Distribution was national — Whole Foods Market, Target, Amazon, iHerb, and Vitacost. No illnesses had been reported at the time of announcement.
This is a supplier-chain recall: Navitas Organics detected the problem through its supplier, not from consumer reports. Salmonella in chia seeds follows a well-documented contamination pathway during harvesting and drying. Food manufacturers using chia seeds from the same supplier network should review their incoming ingredient testing protocols.
FDA Moves to Claim Cosmetic Records Access Under MoCRA
A draft guidance published January 22 addresses FDA's records access authority under the Modernization of Cosmetics Regulation Act (MoCRA). This is part of the ongoing buildout of the cosmetics regulatory framework — the first significant overhaul to cosmetics oversight since DSHEA passed in 1994. The guidance clarifies when and how FDA may request records from cosmetics firms, including during inspections. Comments close March 23, 2026.
Cosmetics companies that haven't yet completed their MoCRA facility registrations and product listings — both mandatory since late 2023 — should treat this guidance as confirmation that FDA is actively building its enforcement infrastructure.
The Bigger Picture
This week's enforcement profile looks routine on the surface — recalls dominating, warning letters in single digits — but the policy layer is significant. Both major press releases this week were framed under MAHA or agency modernization themes: ingredient transparency and import efficiency. That's not coincidence; the new FDA leadership is packaging enforcement and guidance actions as part of a coherent strategic narrative.
Over the trailing 90 days in our dataset, Salmonella (69 actions), Listeria monocytogenes (34), and Clostridium botulinum (29) remain the dominant pathogens driving food recalls. Semaglutide and tirzepatide each account for 29 and 27 actions respectively — primarily warning letters — as the GLP-1 compounding enforcement campaign continues to work through the backlog.
The rare pediatric disease activity also deserves note: FDA issued a Priority Review Voucher for KYGEVVI (doxecitine and doxribtimine) and approved RHAPSIDO (remibrutinib) under voucher in the same week — two pediatric drug milestones in rapid succession. In oncology, a draft guidance on minimal residual disease (MRD) and complete response endpoints for multiple myeloma accelerated approval signals that FDA is continuing to advance surrogate endpoints in hematology.
What to Watch
- Gluten labeling comment window (closes ~March 22, 2026): Docket FDA-2023-P-3942. Any food manufacturer using barley, rye, or shared oat processing should file comments.
- Cosmetics records access guidance (closes March 23, 2026): Comment period for the MoCRA records access draft guidance.
- Cuffless blood pressure device guidance: FDA's draft guidance on clinical performance testing for non-invasive cuffless BP devices (published Jan 23) has implications for the growing consumer wearables sector. Expect comment period to open formally.
- Prodrome Sciences response window: Warning letters citing unapproved/misbranded drug status typically carry a 15-business-day response deadline.
Policy Canary monitors FDA changes for your specific products — by name, by ingredient. Join the pilot program
Get this in your inbox every Friday.
Free FDA intelligence digest. No account required.
